Melissa A. Yopp , Erika Tokita , Kelley Dodson , Bruce K. Rubin
{"title":"The relationship of nasal mucus properties and symptoms in allergic and acute non-allergic rhinitis","authors":"Melissa A. Yopp , Erika Tokita , Kelley Dodson , Bruce K. Rubin","doi":"10.1016/j.amjoto.2024.104569","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Allergic rhinitis (AR) and acute non-allergic rhinosinusitis (ARS) often present with similar symptoms. While these are generally differentiated by history and occasionally by secretion cell counts, there are few data temporally comparing these conditions.</div></div><div><h3>Methods</h3><div>A prospective, observational study was conducted to assess nasal mucus properties, nasal obstruction, nasal secretion cells, and health related QOL during the acute phase (Day 5) and during a later phase of illness (Day 14/28). We screened 280 patients and enrolled 42 subjects (ARS, n = 34; and AR, n = 8) who were otherwise healthy and met eligibility criteria. Nasal secretions for cell count and rheology, and acoustic rhinometry were measured on days 5 and 14 of symptoms. SNOT-20 was administered on Day 5, 14, 10 and 28.</div></div><div><h3>Results</h3><div>In subjects with ARS, there was significantly improved SNOT-20 and major symptom score at day 28 in association with increased nasal cavity volume by acoustic rhinometry and decreased mast cells; all consistent with improvement. However, in subjects with AR there was no symptomatic improvement or change in nasal volume and although there were fewer mast cells and epithelial cells, there was no decrease in the number of eosinophils, neutrophils, or goblet cells in secretions. There was no change in in vitro secretion mucociliary clearability in either group, although values were normal at baseline.</div></div><div><h3>Conclusions</h3><div>These results suggest that nasal symptoms in ARS are improved over 14–28 days with the reduction of mast cells, and increased nasal volume, while in AR, symptoms persist.</div></div>","PeriodicalId":7591,"journal":{"name":"American Journal of Otolaryngology","volume":"46 1","pages":"Article 104569"},"PeriodicalIF":1.8000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Otolaryngology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0196070924003557","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Allergic rhinitis (AR) and acute non-allergic rhinosinusitis (ARS) often present with similar symptoms. While these are generally differentiated by history and occasionally by secretion cell counts, there are few data temporally comparing these conditions.
Methods
A prospective, observational study was conducted to assess nasal mucus properties, nasal obstruction, nasal secretion cells, and health related QOL during the acute phase (Day 5) and during a later phase of illness (Day 14/28). We screened 280 patients and enrolled 42 subjects (ARS, n = 34; and AR, n = 8) who were otherwise healthy and met eligibility criteria. Nasal secretions for cell count and rheology, and acoustic rhinometry were measured on days 5 and 14 of symptoms. SNOT-20 was administered on Day 5, 14, 10 and 28.
Results
In subjects with ARS, there was significantly improved SNOT-20 and major symptom score at day 28 in association with increased nasal cavity volume by acoustic rhinometry and decreased mast cells; all consistent with improvement. However, in subjects with AR there was no symptomatic improvement or change in nasal volume and although there were fewer mast cells and epithelial cells, there was no decrease in the number of eosinophils, neutrophils, or goblet cells in secretions. There was no change in in vitro secretion mucociliary clearability in either group, although values were normal at baseline.
Conclusions
These results suggest that nasal symptoms in ARS are improved over 14–28 days with the reduction of mast cells, and increased nasal volume, while in AR, symptoms persist.
背景:变应性鼻炎(AR)和急性非变应性鼻窦炎(ARS)通常表现出相似的症状。虽然这些通常通过病史和偶尔通过分泌细胞计数来区分,但很少有数据对这些条件进行临时比较。方法:进行前瞻性观察性研究,评估急性期(第5天)和疾病后期(第14/28天)的鼻粘液特性、鼻塞、鼻分泌细胞和健康相关的生活质量。我们筛选了280名患者,纳入了42名受试者(ARS, n = 34;和AR, n = 8),其他方面均健康且符合入选标准。在出现症状的第5天和第14天分别测量鼻腔分泌物细胞计数和流变学,以及声学鼻测量。在第5、14、10和28天给予SNOT-20。结果:ARS患者在第28天SNOT-20和主要症状评分显著改善,听鼻测量结果显示鼻腔体积增加,肥大细胞减少;一切都与改进相一致。然而,在AR患者中,没有症状改善或鼻体积改变,尽管肥大细胞和上皮细胞减少,但分泌物中嗜酸性粒细胞、中性粒细胞或杯状细胞的数量没有减少。两组体外分泌粘液纤毛清除率均无变化,但基线值正常。结论:这些结果表明,随着肥大细胞的减少和鼻体积的增加,ARS的鼻症状在14-28天内得到改善,而AR的症状持续存在。
期刊介绍:
Be fully informed about developments in otology, neurotology, audiology, rhinology, allergy, laryngology, speech science, bronchoesophagology, facial plastic surgery, and head and neck surgery. Featured sections include original contributions, grand rounds, current reviews, case reports and socioeconomics.